The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
The Directors interview and recent high of 8p is good enough to answer your question. However try in small chunks, £1k worth at a time or so.
So basically the are well in business and expanding the business as we speak, and we have bankrupt priced in share price, why would they expand business (routes) after last RNS it they don’t have positive indications for funding from major holders?
I think we are having gifted share price here like last time
...All you need is:
listen to this interview with Director, he is also the CEO of TILS (worth £133 millions in AIM and getting listed in NASDAQ soon. Go to this link: http://okyopharma.com
Our Largest share holder Panitta Partners (47% holder) also a major holder in TILS, Okyo Share price went as high as 8p few weeks ago and Panitta Partners didn’t sell a single share.
Key points from interview:
*Cherimon is permanent cure to dry eyes and big market for it.
* Funded to Develop Cherimon project, spend less money and bring Cherimon up to IND.
* Cherimon project will attract investors and VALUATION of OKYO WILL GO UP, which will attract funding down the road.
*Strong Pipeline 2019 and 2020
From the interview it’s clear, there won’t be any placing until cherimon delivered and Okyo value much higher, not my word, Directors word, listen to the interview and do your own research
Irene, strongsellmanos will not reply anymore as his fake ID is gone lol, did you see another strong sell suggester appeared with 1 post next to them, communicate with him instead lol
“The Dialogue was successful” From the link you posted:
There were prospects though the firm may pull out its operations from the country due to a cash crunch. The Board held talks with the major shareholders and potential investors over the possibility of raising funds to keep the business alive. According to a statement released, the dialogue was successful but did not guarantee a perfect result.
That’s why I think, another premium placing like last time coming in
You must listen to this interview with Director, he is also the CEO of TILS (worth £133 millions in AIM and getting listed in NASDAQ soon. Go to this link: http://okyopharma.com
Key points:
*Cherimon is permanent cure to dry eyes and big market for it.
* Funded to Develop Cherimon project, spend less money and bring Cherimon up to IND.
* Cherimon project will attract investors and VALUATION of OKYO WILL GO UP, which will attract funding down the road.
*Strong Pipeline 2019 and 2020
From the interview it’s clear, there won’t be any placing until cherimon delivered and Okyo value much higher, not my word, Directors word, listen to the interview and do your own research
https://www.medgadget.com/2018/10/dry-eye-syndrome-market-saw-a-dramatic-growth-of-cagr-6-6-usa-and-europe-top-the-list-forecast-2018-2023.html
That’s why Panitta Partners still hold all of their 47% holdings, they didn’t sell anything even when the share price went to 8p, they know the potential.
Panitta Partners is Major share holder of TILS, their market capital £133 millions
https://altcryptotoken.com/dry-eye-disease-market-research-report/11679/
They are well in business then, funding shouldn’t be a problem, if it was then they wouldn’t open new routes, happy with my punt today
That’s probably why people buying today, it’s a decent punt, could multibag easily
Only if you can buy any!
And if they don’t give up Tanzania and come with alternative plans then placing is likely to be at 8p again.